México: Colusión y simulación causa sobreprecios hasta de 98% en medicamentos, denuncia COFECE
Alejandra Palacios, presidenta de la Comisión Federal de Competencia Económica (COFECE) de México, declaró que la falta de competencia y el abuso en poder de mercado de ciertas empresas farmacéuticas y autoridades públicas ha significado que “los hogares mexicanos pagan en promedio 98 por ciento más de lo que pagarían sin sobreprecios” en la compra de medicamentos.
Featured News
Apple Eases EU Tracking Rules After Antitrust Scrutiny
Sep 17, 2026 by
CPI
FTC Moves to Restrict Beretta’s Board Influence in Ruger Investment
Sep 17, 2026 by
CPI
Justice Department Open to Talks With AI Labs on Safety Coordination
Sep 17, 2026 by
CPI
Hogan Lovells Cadwalader Adds Skadden Antitrust Partner in Brussels Push
Sep 17, 2026 by
CPI
Paramount Threatens California Exit as Warner Bros. Antitrust Fight Escalates
Sep 17, 2026 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Computational Antitrust
Sep 16, 2026 by
CPI
The Next Five Years of Computational Antitrust
Sep 16, 2026 by
Thibault Schrepel
When Two AI Agents Talk: A Gap in Detection Capabilities
Sep 16, 2026 by
Alba Ribera Martinez
When Innovation Competition Has No Product Yet: Making General Innovation Competition Operational
Sep 16, 2026 by
Mariateresa Maggiolino
Computational Antitrust for Complex Adaptive Markets
Sep 16, 2026 by
Filip Lubinski